

Index

a

- ABO blood group
 - blood type with higher susceptibility 154, 155
 - COVID-19 clinical outcomes, of severity 154, 156
 - genetics 154
 - influenza viruses 154
 - molecular mechanisms of 154, 158
 - and Rh factor 153–154, 157
 - SARS 154
- Acalabrutinib 115, 309–310
- Accelerating COVID-19 Therapeutic Interventions and Vaccines-3 (ACTIV-3) 198
- ACE2. *See* Angiotensin-converting enzyme 2 (ACE2)
- ACEis. *See* Angiotensin-converting enzyme inhibitors (ACEis)
- ACoCS. *See* Acute COVID-19 cardiovascular syndrome (ACoCS)
- Acute cerebrovascular events 351–352
- Acute coronary syndrome (ACS) 201, 363, 364
 - clinical manifestations of 364–365
 - diagnosis of 365
- Acute COVID-19 cardiovascular syndrome (ACoCS) 372–373
- Acute disseminated encephalomyelitis (ADEM) 348, 497
- Acute kidney injury (AKI) 137–138, 203
- Acute myelitis 350–351
- Acute myocarditis 368–369
- Acute respiratory distress syndrome (ARDS) 81, 83, 101, 118, 126, 187, 188, 238–239, 245, 292, 324, 457, 461
 - corticosteroids and 239–240
 - extracorporeal membrane oxygenation for 240–241
 - Network trial 458
 - prone positioning 239
 - rescue therapies for 189–190
- Adaptive Covid-19 Treatment Trial (ACTT-1) 192, 195, 273, 378
- Adaptive immune response. *See* Immune response
- Ad26.CoV2.S vaccine 479
- ADEM. *See* Acute disseminated encephalomyelitis (ADEM)
- Adenovirus vector technology 10
- Adjunctive therapy 275–276
- Ad5-nCoV vaccine 479
- Advance care planning 461–462
- Aerosol-generating procedures (AGPs) 235–236
 - bronchoscopy 204–205
 - cardiopulmonary resuscitation 206–207
 - tracheostomy tube 205–206
- Aerosolization 3–4, 183
- Aerosols 28
- Affordable Care Act 587
- Africa, healthcare systems in 619–620, 624–625
- AGPs. *See* Aerosol-generating procedures (AGPs)
- Air bubble sign 73–74
- Airways dilation 72
- Alinia. *See* Nitazoxanide
- Alphacoronavirus* 23, 24
- ALVEOLI study 187
- Ambulatory testing 268
- American College of Cardiology (ACC) guidelines 365, 366, 369

- American College of Radiology (ACR) 64, 90
- American College of Rheumatology 277
- American Heart Association (AHA) guidelines 365, 366, 369
- American Medical Association 582
- American school system 590–592
- American Society for Radiation Oncology 397
- American Society for Transplantation and Cellular Therapy 397
- American Society of Clinical Oncology (ASCO) 393–395
- American Society of Emergency Radiology (ASER) 64–65
- American Society of Hematology 401
- Anakinra 198
- Anatomical progression, of COVID-19 112–114
- Ang(1-7) 300–301
- Angiotensin-converting enzyme 2 (ACE2) 26, 27, 37, 168, 291, 362, 364, 378
 - across human genome databases 150
 - expression level 108, 128, 129, 136, 138, 341
 - in GI tract 131–132
 - mutations 342
 - on pneumocytes and endothelial cells 125
 - recombinant 300
 - SARS-CoV-2-mediated reduction of 301
 - in small intestine 107
 - with spike (S) protein 112
- Angiotensin-converting enzyme inhibitors (ACEis) 378, 379
- Angiotensin II (AngII) 299
- Angiotensin receptor blockers (ARBs) 299, 378, 379
 - Ang(1-7) 300–301
 - losartan 299–300
 - recombinant ACE2 300
 - telmisartan 300
 - valsartan 299
- Angiotensin type 1 receptor (AT1R) 299, 300
- Animal hosts 2–3
- Antabuse. *See* Disulfiram
- Antibody-dependent cellular cytotoxicity 118
- Antibody testing 51
 - for COVID-19 44
 - in SARS-CoV-2 52–53
- Anticoagulation 168–169, 244
- Anticytokine therapy
 - GM-CSF antagonism 307–308
 - IL-6 antagonism 307
 - IL-1 receptor antagonism 306–307
 - IL-6 receptor antagonism 307
- Antiepileptic drugs (AEDs) 349
- Antigenicity 25–26
- Antigen testing 41–42
- Anti-IL-6 mAbs 175
- Anti-inflammatory therapies 169
 - acalabrutinib 309–310
 - baricitinib 310
 - cyclosporine 309
 - for hospitalized patients
 - baricitinib 195
 - colchicine 196
 - glucocorticoids 194–195
 - tocilizumab 195–196
 - lenzilumab 310
 - steroids 309
- Anti-SARS-CoV-2 mAbs 169–170
 - bamlanivimab plus etesevimab 170–171
 - bebtelovimab 171
 - casirivimab plus imdevimab 171
 - distribution of 171–172
 - for mild-to-moderate outpatient 169–170
 - side effects of 171
 - sotrovimab 171
- Anti-sperm antibodies (ASAs) 139
- Antiviral therapy 273, 293, 297
- Anxiety/depression 540–542
- Aphonia 128
- ARB. *See* Angiotensin receptor blockers (ARB)
- ARDS. *See* Acute respiratory distress syndrome (ARDS)
- ARDSNet protocol 187
- Arrhythmias 202, 373–374
- Arterial vasoconstriction 529
- ASCO Expert Panel 402
- Asia-Pacific region, healthcare systems in 625, 626
 - Central Asia 627
 - East Asia 625–627
 - future directions 629
 - Oceania/Pacific region 628–629
 - South Asia 627–628
 - Southeast Asia 628
- As Low As Reasonably Achievable (ALARA) 69
- Aspergillus fumigatus* 325

Aspergillus superinfection 324
 Aspiration 84
 AstraZeneca vaccine 137
 Asymptomatic transmission 5
 Atoll sign/reverse halo sign 73
 Atypical pneumonias 85
 Auranofin 115
 Autoimmune encephalitis, pathogenetic mechanism of 349–350
 Autonomic dysfunction 374, 375
 Avigan. *See* Favipiravir
 Awake proning 185
 AZD1222 vaccine 479, 483
 Azithromycin (AZM) 175, 196–197, 298–299, 302, 305, 378

b

BACC Bay trial 196
 Bacterial co-infections 319–320
 Klebsiella pneumoniae 320, 321
 Legionella co-infection 323–324
 Mycoplasma pneumoniae 320, 322
 Pseudomonas aeruginosa 322
 Streptococcus pneumoniae 320
 Bafinivirus 24
 BALF. *See* Bronchoalveolar lavage fluid (BALF)
 Bamlanivimab 198, 271, 391, 487
 Bamlanivimab plus etesevimab 115, 170–171
 Baricitinib 115, 195, 276, 310, 392
 Bat-CoV RaTG13 2
 Battle Buddy system 573, 574
 BBIBP-CorV vaccine 478, 484
 Bebtelovimab 171
 Betacoronavirus 23, 24, 25, 27
 Bilevel positive airway pressure (BiPAP) 457–458
 Biologics, cancer therapy 396
 Biomarker 440
 BI-RADS. *See* Breast Imaging-Reporting and Data System (BI-RADS)
 Bloodborne transmission 4
 Blood-brain barrier (BBB) 341
 BNT16b2 (Pfizer-BioNTech) vaccine 53, 115, 116, 475, 476, 481–482, 509
 Brain, histopathologic findings in 108–109

Brazil, disparities in exposure risk 595–596
 Brazilian healthcare system 595
 Brazilian Institute of Geography and Statistics 595
 Brazilian TOGETHER trial 174
 Breastfeeding, during COVID-19 137, 258
 Breast Imaging-Reporting and Data System (BI-RADS) 394, 499, 502
 British Rhinology Society Consensus 127
 British Thoracic Society (BTS) 525
 Bronchial wall thickening 72–73
Bronchiectasis 72
 Bronchoalveolar lavage fluid (BALF) 37
 Bronchopneumonia 72–73
 Bronchoscopy 204–205
 Bruton's tyrosine kinase (BTK) inhibitors 276, 309, 396
 B-type natriuretic peptide (BNP) 152
 Budesonide 174
 Building resilience 467
 Bull's-eye sign 73
 Buteyko method 530

c

Calprotectin 151–152
 Camostat (CM) 293, 297
 Cancer
 biologics 396
 cellular therapy 397–398
 clinical, serologic, and imaging considerations 390–391
 clinical trials 399
 cytotoxic chemotherapy 395–396
 hematopoietic cell transplantation 397–398
 history of 389–390
 immunotherapy 396
 management of patients with 393–394
 oncologic surgery 398–399
 palliative care 403
 in postpandemic 403
 radiotherapy 396–397
 screening and diagnosis 394–395
 supportive care 401–402
 survivorship and surveillance 402–403
 targeted agents 396
 telemedicine 402

- therapeutics 391
 - baricitinib 392
 - convalescent plasma 392
 - glucocorticoid 391–392
 - molnupiravir 392–393
 - monoclonal antibodies 391
 - remdesivir 391–392
 - tocilizumab 392
- thromboembolism 399
- vaccinations 399–401
- Candida* infections 204
- Cardiac biomarkers 202
- Cardiac disease 532–533
 - complications 201–203
 - management 272
- Cardiogenic shock 368–369
- Cardiopulmonary exercise testing (CPET) 516, 526, 531
- Cardiopulmonary resuscitation (CPR) 206–207, 236–237
- Cardiovascular diseases
 - acute coronary syndrome 363
 - arrhythmias 373–374
 - chronic heart failure 379–380
 - epidemiology 362
 - heart transplant recipients 380
 - inflammatory syndromes 371–373
 - long-term management 376–377
 - microvascular injury 362
 - multiple mechanisms 362, 363
 - myocardial injury (*See* Myocardial injury)
 - overview of 361
 - oxygen supply and demand mismatch 363–364
 - PASC infection 375–376
 - POTS 374–375
 - systemic hyperinflammatory response 364
 - treatment strategies 377–379
- Cardiovascular system, gross and histopathologic findings in 105, 106
- Caribbean region, healthcare systems in 640
- Case fatality rate (CFR) 5, 362
- Casirivimab 391, 487
- Casirivimab plus imdevimab 115, 171
- CBT. *See* Cognitive behavioral therapy (CBT)
- CDC. *See* US Centers for Disease Control and Prevention (CDC)
- Cell surface signaling 119
- Cellular therapy 397–398
- Central Africa, healthcare systems in 623–624
- Central America, healthcare systems in 638–639
- Central Asia, healthcare systems in 627
- Central line-associated bloodstream infection (CLABSI) 203–204
- Central nervous system (CNS)
 - ACE-2 expression, direct infection through 341
 - hematogenous pathway 341
 - hypoxia 343
 - neuroinflammation 342–343
 - neuronal infection 341–342
 - retrograde pathway, through neurons 340–341
- Central pulmonary artery enlargement 76–77
- Central retinal artery occlusions (CRAOs) 422
- Central retinal vein occlusion (CRVO) 421–422
- Centrilobular nodules 81–83
- Cerebral venous sinus thrombosis (CVST) 505–507
- Cerebrospinal fluid (CSF) 37, 345, 346, 348–349
- ChAdOx1 vaccine 479, 483
- Chemiluminescent immunoassays (CLIAs) 45, 47
- Chemokines 303
- Chest computed tomography (chest CT) 70, 518, 519
 - acute infection 521
 - long-term follow-up 523–525
 - mid-term follow-up 523, 524
 - pathologic findings after discharge 525
 - recovery trajectories 522
 - short-term follow-up 521–523
- Chest x-ray (CXR) 62, 64, 66–69, 261, 320, 323, 518, 519, 530
- Chilblain-like lesions (CLLs) 413
- Chimeric antigen receptor T cell (CAR T cell) therapy 292
- China
 - disparities in exposure risk 592
 - healthcare workers impact in 556–557
 - SARS-like viruses 2
- Chinese Society of Anesthesiology Task Force on Airway Management 185
- Chloroquine (CQ) 175, 298–299, 459
- Chronic heart failure 379–380
- CLABSI. *See* Central line-associated bloodstream infection (CLABSI)

- CLIAAs. *See* Chemiluminescent immunoassays (CLIAs)
- Clofazimine 311–312
- Clostridium difficile* 243
- CNN. *See* Convolutional neural network (CNN)
- CNS. *See* Central nervous system (CNS)
- Cognitive behavioral therapy (CBT) 541, 545–546
- Colchicine 176, 196
- COMET-ICE trial 171
- Community-Acquired Pneumonia: Evaluation of
Corticosteroids in Coronavirus Disease
(CAPE-COVID) 194
- Compassion fatigue 403
- Computed tomography (CT) 62, 64, 516
alternative diagnosis 81, 82
ARDS 83
aspiration 84
atypical pneumonias 85
centrilobular nodules 81–83
chest (*See* Chest CT)
DAH 86
diagnostic performance of 70
differential diagnosis 86
dual-energy CT 75–77
eosinophilic pneumonias 86–87
imaging protocol 69–70
isolated segmental/lobar consolidation 81
lung cavitation 83
lymphadenopathy 77–78
NSIP 85–87
organizing pneumonia 84
pleural effusions 83
pneumothorax/pneumomediastinum 83
pulmonary edema 86
pulmonary parenchymal manifestations 70–74
pulmonary vascular manifestations 74–77
risk stratification 87–88
spectral 75
superinfection 83, 84
temporal evolution 78–79
absorption stage 79
axial computed tomography images 80
early stage 79
fibrotic-like findings 81
peak stage 79
progressive stage 79
time course of 518
viral pneumonias 84, 85
- Computed tomography pulmonary angiography
(CTPA) 69
- Conjunctivitis 417–418
- Consolidation 71, 81, 85
- Consultation Multi-Expertise de Bicêtre Après
COVID-19 (COMEBAC) 523
- Contact tracing 53, 583
- Contingency capacity 455
- Continuous positive airway pressure (CPAP)
435, 438
- Convalescent plasma therapy 176, 193, 275,
308–309, 392, 487
- Conventional capacity 455
- Conventional ventilation/ECMO for Severe Adult
Respiratory failure (CESAR) 190
- Convidecia vaccine 479
- Convolutional neural network (CNN) 158, 159
- Corneal graft rejection 419
- CoronaVac (Sinovac) 10, 478, 484
- Coronaviridae* 23–25
- Coronavirineae* 23–25
- Coronavirus (CoV) 22
antigenicity 25–26
classification of 24
morphology 24–25
nucleic acid 25
structure of 24
taxonomy 23–24
timeline of 22, 23
- Corticosteroids 239–240, 274, 414
- COVACTA trial 196
- Covaxin/BBV152 vaccine 10, 478
- COV-BARRIER trial 195
- COVID-19 Dexamethasone (CoDEX) trial 194
- COVID-19 Reporting and Data System (CO-RADS)
92, 519
- COVIDSeq Test 41
- “COVID-19: Thoracic Imaging Findings and
Recommendations” 65
- COVID-19 Vaccines Global Access (COVAX)
624–625
- Covishield vaccine 479, 483
- CoV-like particle (CoVLP) vaccine 481

Cozaar. *See* Losartan
 CPET. *See* Cardiopulmonary exercise testing (CPET)
 CPR. *See* Cardiopulmonary resuscitation (CPR)
 CRAOs. *See* Central retinal artery occlusions (CRAOs)
 Crazy paving 71–72, 79
 Crisis capacity 455
 Crisis standard of care 580–581
 CRISPR-Cas technology 40
 Critical illness, epidemiology of
 defined 233–234
 mortality 234–235
 risk factors, for severe disease 234
 Cross-sectional imaging 67
 CRS. *See* Cytokine release syndrome (CRS)
 CRVO. *See* Central retinal vein occlusion (CRVO)
 CSF. *See* Cerebrospinal fluid (CSF)
 CT angiography (CTA) 505–507
 Cutaneous emphysema 424
 CVnCoV (CureVac) vaccine 476
 CVST. *See* Cerebral venous sinus thrombosis (CVST)
 Cycle threshold (Ct) 38
 Cyclosporine 115, 309
 Cytokine release syndrome (CRS) 292, 342–343
 Cytokine storm 118–119, 192
 Cytopathic effects (CPEs) 42
 Cytotoxic chemotherapy 395–396

d

DAD. *See* Diffuse alveolar damage (DAD)
 D-dimer levels 74, 151, 368, 507
 Deep learning 159
 Deep vein thrombosis (DVT) 367
 Defense Production Act 638
 Delirium, management of 548
 Deltacoronavirus 23, 24
 Demographics
 age 7, 8
 overview 7
 race and ethnicity 7, 9–11
 sex 7, 8
 Dengue 331–333
 Depression/anxiety 540–542
 Depression, Anxiety, and Stress Scale short-form (DASS-21) 560
 Dermatological diseases
 corticosteroids 414
 cutaneous manifestations of
 chilblain-like lesions 413
 classifications/categorization 409–411
 erythema multiforme 412
 exanthem group 411
 maculopapular rash 411, 412
 miscellaneous 413–414
 urticarial rash 411, 412
 vascular lesions 412–413
 vasculitic lesions 413
 vesicular pattern 411–412
 immunosuppressants 414
 patient registries 414
 personal protective measures 409, 414
 DEXA-ARDS study 239
 Dexamethasone (DEX) 115, 175, 274, 309
 Diagnostic disparities
 in COVID-19 testing 597–598
 imaging utilization, role of 598
 Diffuse alveolar damage (DAD) 101–103
 Diffuse alveolar hemorrhage (DAH) 86
 Diffusing capacity for carbon monoxide (DLCO) 517, 527
 Diovan. *See* Valsartan
 Discharge planning 463–464
 Disparities, in exposure risk
 Brazil 595–596
 China 592
 clinical
 hospitalizations and inpatient admissions 598–599
 ICU admission 599–600
 treatment disparities 600–601
 diagnostic 597–598
 India 594–595
 Iran 596–597
 Italy 592–594
 in patient outcome 601–603
 United States 586–587
 diagnostic disparities 597–598
 education 590–592
 neighborhood and environment 588–589
 prison and correctional system 589–590

Disparities, in exposure risk (*cont'd*)
 racial and ethnic disparities 587–588, 591
 tribal and rural communities 589
 unemployment and occupational risk 589
 in vaccination 603–607
 Disulfiram 304
 DLCO. *See* Diffusing capacity for carbon
 monoxide (DLCO)
 DNA Endonuclease-Targeted CRISPR Trans Reporter
 (DETECTR) 40
 Dual-energy CT (DECT) 75–77
 Dutch Radiological Society 92
 Dysphagia 444
 Dysphonia 128
 Dyspnea, workup and management of
 nonresolving 531

e

East Africa, healthcare systems in 621–622
 East Asia, healthcare systems in 625–627
 Ebola virus disease (EVD) 616
 ECMO. *See* Extracorporeal membrane
 oxygenation (ECMO)
 ECMO to Rescue Lung Injury in Severe ARDS
 (EOLIA) study 190
 EIDD-2801. *See* Molnupiravir
 Electrolytes 272
 Electromyography/nerve conduction study
 (EMG/NCS) 346
 Electron microscopy (EM) 106
 ELISAs. *See* Enzyme-linked immunosorbent type
 assays (ELISAs)
 Emergency Use Authorization (EUA) 39, 40, 42,
 271, 274–276, 308
 EMG/NCS. *See* Electromyography/nerve conduction
 study (EMG/NCS)
 Empathy 403
 Encephalitis 347, 348
 Encephalopathy 346–349
 meningoencephalitis 349–350
 metabolic 350
 Endomyocardial biopsy 369
 Endotracheal intubation 186
 Endotracheal tubes (ETTs) 186, 187, 206
 Energy expenditure, estimation of 440, 442
 Enteral nutrition (EN) 431, 439, 440, 446
 Enzyme-linked immunosorbent type assays
 (ELISAs) 45–47
 Eosinophilic pneumonias 86–87
 Epidemiology 1–2
 animal hosts 2–3
 asymptomatic transmission 5
 case fatality rate 5
 of critically ill patients 233–235
 demographics 7–11
 disease prevention
 air quality and ventilation 14
 hand and surface sanitation 13–14
 outdoor spaces, use of 114
 personal protective equipment 12–13
 physical distancing 13
 vaccinations 10, 12
 excess mortality 6
 geographic distribution 14
 infectivity and incubation 3
 international response 14–15
 origin 2
 pandemic playbook 15
 reproduction number/reproduction ratio 5–6
 serial interval 5
 transmission modes 340
 aerosolization 3–4
 bloodborne 4
 direct surface contact and fomites 4
 fecal-oral 4
 respiratory droplets 3
 semen and vaginal secretions 4–5
 Epinephrine 237
 Episcleritis 418
 EpiVacCorona vaccine 480, 484–485
 Erectile dysfunction 138
 Erythema multiforme 412
Escherichia coli 83
 Etanercept 115
 Etesevimab 391
 Ethical considerations, in clinical practice
 contact tracing 583
 crisis standard of care 580–581
 healthcare providers, duty of 582
 off-label use, of drugs 582–583

overview of 580
 pseudoscientific claims 582
 resource allocation 581
 Ethnic disparities 587–588
 ETTs. *See* Endotracheal tubes (ETTs)
 EUA. *See* Emergency Use Authorization (EUA)
 Euler-Liljestrand mechanism 77
 European Society for Clinical Nutrition and
 Metabolism (ESPEN) guidelines 440
 Europe, healthcare systems in 629–632
 Evaluating Minority Patients with Actemra
 (EMPACTA) trial 195
 Exanthem group 411
 Excess mortality 6, 619
 Exo-CD24 311
 Experimental therapeutics
 clofazimine 311–312
 Exo-CD24 311
 fluvoxamine 311
 PAC-MAN 310
 single-domain antibodies 311
 Extracorporeal Life Support Organization
 (ELSO) 241
 Extracorporeal membrane oxygenation (ECMO)
 190–192, 240–241, 439

f

FACE COVID 467
 Facial nerve 131
 FACTT trial 188
 Favipiravir 301
 FDG. *See* ¹⁸F-fluorodeoxyglucose
 Fecal-oral transmission 4
¹⁸F-fluorodeoxyglucose (FDG) 520
¹⁸F-fluorodeoxyglucose (FDG) PET/CT imaging
 89, 499–501
 Fibrin microthrombi 102, 103
 Fleischner lexicon 71
 Fleischner Society 61–63
 Flow phase 440
 Fluid-attenuated inversion recovery (FLAIR)
 346, 349
 Fluids 272
 Fluvoxamine 173–175, 311
 Foipan. *See* Camostat (CM)

Food service system 446
 Forced vital capacity (FVC) 517
 Fosun Pharma 475, 481–482
 Fraction of inspired oxygen (Fio₂) 526
 French Society for Oncology Pharmacy 392
 Frontline healthcare workers 561–562
 Fungal superinfection 324
 histoplasmosis 329–330
 mucormycosis 326–327
 Pneumocystis jirovecii pneumonia 327–328
 pulmonary aspergillosis 324–325
 Trichosporon asahii fungemia 328–329

g

GAD. *See* Generalized anxiety disorder (GAD)
 Gamaleya Research Institute of Epidemiology and
 Microbiology, Russia 483–484
Gammacoronavirus 23, 24
 Gastric residual volumes (GRVs) 443
 Gastrointestinal (GI) tract
 histopathologic findings in 107–108
 intolerance 443–444
 manifestation, of COVID-19 131–134
 Generalized anxiety disorder (GAD) 561, 565, 567
 Genetics 154
 German Society of Thrombosis and
 Hemostasis 507
 GGOs. *See* Ground-glass opacities (GGOs)
 GISAID EpiCov database 41
 Glucocorticoid therapy 194–195, 274, 391–392
 Granulocyte-macrophage colony-stimulating factor
 (GM-CSF) 119, 306
 antagonism 307–308
 Granulomatous reaction 495–496
 GRECCO-19 196
 Ground-glass opacities (GGOs) 70–71, 79, 85, 87,
 320, 328, 331, 334, 516–519, 521, 523, 524
 Guillain-Barré syndrome (GBS) 129, 343,
 345–346, 505

h

Halo sign 73
 HCQ. *See* Hydroxychloroquine (HCQ)
 HCWs. *See* Healthcare workers (HCWs)
 Healthcare providers, duty of 582

Healthcare systems

- Africa 619–620, 624–625
- Americas 634, 636, 637
 - Caribbean region 640
 - Central America 638–639
 - further directions for 640–641
 - North America 636–638
 - South America 639–640
- Asia-Pacific 625, 626
 - Central Asia 627
 - East Asia 625–627
 - future directions 629
 - Oceania/Pacific region 628–629
 - South Asia 627–628
 - Southeast Asia 628
- Central Africa 623–624
- before COVID-19 615–617
- cumulative cases 618
- East Africa 621–622
- Europe 629–632
- international trends and collaboration 617–619
- MENA region 632–636
- Southern Africa 622–623
- West Africa 620–621
- Healthcare workers (HCWs) 235, 236, 242
 - in Africa 620, 624
 - frontline 561–562
 - non-frontline 565
 - psychological impact on (*See* Mental health effects, for HCWs)
 - sleep dysfunction in 555
 - worldwide survey of 618, 619
- Hearing loss 129–131
- Heart failure 201–202
- Heart transplant recipients 380
- Hemagglutinating encephalomyelitis virus (HEV) 341, 342
- Hemagglutinin esterase (HE) protein 25, 26
- Hematogenous pathway 341
- Hematology 272
- Hematopoietic cell transplantation (HCT) 397–398
- Hemodynamic support 237
- Hepatic injury 133
- Herd immunity 12

- High-flow nasal cannula (HFNC) 183–187, 272, 435, 438, 457–459
- High-flow oxygen (HFO) 235
- High-resolution CT (HRCT) 516–519
 - long-term follow-up with 525
 - radiographic abnormalities correlated with 524
 - three-month follow-up 523
- Histopathologic findings
 - brain 108–109
 - cardiovascular system 105, 106
 - gastrointestinal tract and liver 107–108
 - kidney 105–107
 - respiratory system 101–104
 - skin 109
- Histoplasma capsulatum* 330
- Histoplasmosis 329–330
- H1N1 influenza pandemic 27
- HOME-CoV Rule 166
- Home monitoring 167
- Home supplemental oxygen, use of 169
- Hospitalized patients. *See* Inpatient management
- HRCT. *See* High-resolution CT (HRCT)
- Humanization of care 465–466
- Human leukocyte antigen D-related (HLA-DR) 118
- Hydroxychloroquine (HCQ) 175, 275, 377, 378, 459
 - azithromycin with/without 196–197, 305
 - chloroquine and 298–299
- HyperCKemia 346
- Hypercoagulability 138
- Hyperglycemia 430, 443
- Hyperinflammation, vs. MIS-C 270
- Hyperventilation syndrome 516, 527, 529–530, 533
- Hypoglycemia 242

i

- Idiopathic pulmonary fibrosis 531
- IDSA. *See* Infectious Diseases Society of America (IDSA)
- IFD. *See* Invasive fungal disease (IFD)
- IFN. *See* Interferon (IFN)
- IHCAs. *See* In-hospital cardiac arrests (IHCAs)
- Imaging Councils 402
- Imdevimab 391, 487
- Immune dysregulation

Immune response

- anatomical progression 112–114
- antibody-dependent cellular cytotoxicity 118
- cytokine storm 118–119
- dysregulation 118
- immunologic correlates of protection 113, 116
- interferon, autoantibodies against type I 117
- in nasal passages and lungs 113
- therapeutics 115
- vaccine-induced 116
- viral dissemination 116–117
- viral evasion 117
- to viruses and immunization 113

Immune thrombocytopenia (ITP) 401

Immunogenicity 473–474

Immunoglobulin 44, 50

Immunoglobulin G (IgG) 113, 117

Immunoglobulin M (IgM) 113

Immunohistochemistry (IHC) 104

Immunosuppressants 414

Immunotherapy 306, 396

Inactivated vaccines 10, 478

InceptionV3 Model 158, 159

India

- disparities in exposure risk 594–595
- healthcare workers impact in 559

Indian Council of Medical Research 595

Indian Health Service 597

Infection prevention and control, in ICU 235–236

Infectious Diseases Society of America (IDSA) 192, 273, 377, 378, 597

Infertility 139

Influenza A virus (IAV) 331

Influenza B virus (IBV) 331

Influenza virus 154, 331, 341

Inhaled pulmonary vasodilators 189, 190

In-hospital cardiac arrests (IHCAs) 236–237

Injection-site reaction 503

Innate immune system 117

INO-4800 vaccine 477

Inpatient management 272

- anakinra 198
- anti-inflammatory therapies
 - baricitinib 195
 - colchicine 196

glucocorticoids 194–195

tocilizumab 195–196

azithromycin 196–197

critically ill patient, caring for

- intubating patients, practical considerations for 186–187
- intubation strategies 185–186
- mechanical ventilation 187–188
- refractory hypoxemia, of ventilated patients 188–191

extrapulmonary disease, in acutely ill patients 199

- cardiac complications 201–203
- infectious complications 203–204
- renal complications 203
- thromboembolic disease 200–201

hospitalization 182–183

hydroxychloroquine 196–197

interferons 197–198

lopinavir and ritonavir 197

monoclonal antibody 198–199

nursing

- adjusting nursing practices 455
- limiting hospital visits 455
- medications 459–461
- nutritional management 461
- oxygen delivery, modes of 457–459
- personal protective equipment 454–455
- pressure-related injuries 459
- prone positioning intubated patients 457
- prone positioning spontaneously breathing patients 456–457
- reducing nonessential visits 456
- staffing issues 455–456

patient placement and care

- biocontainment units 207, 208
- clean zones 207–208
- dirty zones 207–209
- increasing ICU capacity 209–211
- management considerations 212

performing aerosol-generating procedures

- bronchoscopy 204–205
- cardiopulmonary resuscitation 206–207
- tracheostomy tube 205–206

pharmacologic therapies 191–192

convalescent plasma 193

Inpatient management (*cont'd*)
 ivermectin 193–194
 remdesivir 192
 respiratory support
 awake proning 185
 noninvasive 183–185
 treatment recommendations 199
 INSPIRATION trial 201
 Institutional protocols 235
 Insulin resistance 430
 Intensive care unit (ICU)
 admission 581, 599–600
 anticoagulation 244
 beds occupied, percentages of Spanish 601
 cardiopulmonary resuscitation 236–237
 dysphagia 444
 epidemiology, of critically ill patients 233–235
 hemodynamic support 237
 inadequate nutrition during and after 429
 infection prevention and control 235–236
 multidisciplinary care 444
 nutrition algorithm 441
 nutritional support in 242
 post-intensive care syndrome 244–245
 in prepandemic times 454
 releasing patient from 581
 respiratory failure management 237–239
 standard ICU care 242–244
 tocilizumab 240
 tracheostomy placement 241–242
 venous thromboembolism 244
 Interdisciplinary care team (ICT) 462
 Interferon (IFN) 197–198, 306
 autoantibodies against type I 117
 Interleukin-1 (IL-1) receptor antagonism 306–307
 Interleukin-6 (IL-6) 118, 152, 275, 307, 460
 Interleukin-10 (IL-10) 152
 Interleukin-15 (IL-15) 152
 Interlobular septal thickening and intralobular
 lines 71
 International Cardio-Oncology Society 402
 International Committee on Taxonomy of
 Viruses 23
 International Medical Prevention Registry on Venous
 Thromboembolism (IMPROVE) 169

International risk, for exposure to COVID-19
 Interstitial lung disease (ILD) 522
 Intravenous immunoglobulin (IVIG) 277, 346
 Intubation 238
 Invasive fungal disease (IFD) 324, 325
 Invasive mechanical ventilation (IMV) 192, 194,
 438, 439
 Invasive pulmonary aspergillosis (IPA) 324, 325
 Iran
 disparities in exposure risk 596–597
 healthcare workers impact in 560–561
 Isolated consolidation 81
 Italy, disparities in exposure risk 592–594
 Ivermectin 175, 193–194, 275, 305
 IVIG. *See* Intravenous immunoglobulin (IVIG)
 IV infusion pumps 212

j

Janus kinase (JAK) inhibitors 175, 276
 JNJ-78436735 (J&J Janssen) vaccine 115
 Johnson & Johnson/Janssen COVID-19
 vaccine 505
 induced immune thrombotic thrombocytopenia
 505–507

k

Kaiser Family Foundation 597
 Kawasaki disease 256, 266, 371–373
 Kidney, histopathologic findings in 105–107
 Kinase inhibitors 276
Klebsiella pneumoniae 320, 321

l

Laboratory/serologic diagnostics
 antibody testing 44
 antigen testing 41–42
 molecular diagnostics 36–40
 sequencing techniques 40–41
 viral culture 42–43
 Labyrinthitis 130
 Lamprene. *See* Clofazimine
 LAP. *See* Lymphadenopathy (LAP)
 Laryngitis 128
 Lateral flow type assays (LFAs) 45–47
 Layered prevention strategy approach 590
Legionella co-infection 323–324

Lenzilumab 310
 Leydig cells 139
 Limit of detection (LoD) 39
 Liver, histopathologic findings in 107–108
 Long COVID 101
 symptoms 131
 syndrome 516, 548
 Long-term management, of cardiovascular disease 376–377
 Long-term pulmonary consequences 516
 chest CT 518, 519
 acute infection 521
 long-term follow-up 523–525
 mid-term follow-up 523, 524
 pathologic findings after discharge 525
 recovery trajectories 522
 short-term follow-up 521–523
 chest x-ray 518, 519
 clinical management 530–533
 MERS 517
 pathophysiology 525
 hyperventilation syndrome 527, 529–530
 lung perfusion 527
 muscular deconditioning and weakness 526
 occult myocardial damage 526–528
 post-COVID pulmonary fibrosis 525–526
 pulmonary vascular disease 527
 PET-CT 518, 520–521
 pulmonary MRI 519–520
 radiographic signature 518
 severe acute respiratory syndrome 516–517
 Lopinavir 175–176, 197, 304
 Losartan 299–300
 Low-dose CT (LDCT) imaging 519, 525
 Low-flow oxygen systems 183–184
 Low-molecular-weight heparin (LMWH) 368
 Lungs
 adaptive immune response in 113
 cavitation 83
 injury 188
 Lung ultrasound (LU), 88–89sss
 Lymphadenopathy (LAP) 77–78, 495, 496, 498
 after vaccination 502
 imaging in 498–501
 Lymphocytic myocarditis 105

m

Machine learning (ML) method 158–159
 Macrophage activation-like syndrome (MAL) 343
 Maculopapular rash 411, 412
 Magnetic resonance imaging (MRI) 89–90
 cardiac 527, 528
 pulmonary 519–520
 Major depressive disorder (MDD) 565
 Malayan pangolins (pangolin-CoV-GDC) 28
 Malnutrition screening 430–431
 Mean arterial pressure (MAP) 237
 Mechanical ventilation 187–188, 457–459
 Medical professionalism 562–564, 582
 Meningitis 347–348
 Meningoencephalitis 349–350
 Mental health effects, for HCWs 554–555
 China 556–557
 frontline healthcare workers 561–562
 India 559
 interventions and strategies 570
 individual level 5733–575
 institutional level 571–573
 international, national, and regional levels 570–571
 Iran 560–561
 medical professionals 562–564
 nonclinical healthcare personnel 565
 non-frontline healthcare workers 565
 nursing staff 564–565
 overview of 555–556
 risk factors 565–566
 age 567
 gender 566
 infection among respondents 568
 living circumstances 568
 poor sleep 568, 569
 PPE 568–570
 precautions at home 567–568
 underlying medical conditions 567
 Southeast Asia 561
 United Kingdom 558–559
 United States of America 557–558
 Mental Health Gap Action Program Humanitarian Intervention Guide 573

- MERS-CoV. *See* Middle Eastern respiratory syndrome coronavirus (MERS-CoV)
- Messenger RNA (mRNA) vaccine 394, 399–400
- Metabolic encephalopathy 350
- Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (METCOVID) trial 194
- Micardis. *See* Telmisartan
- Microvascular injury 102–103, 362
- Middle East and North Africa (MENA) 632–636
- Middle Eastern respiratory syndrome coronavirus (MERS-CoV) 1, 22–23, 34, 35, 291, 517
- Middle East respiratory syndrome (MERS) 1, 184, 459, 515, 517, 522, 616
- MIS-A. *See* Multisystem inflammatory syndrome in adults (MIS-A)
- MIS-C. *See* Multisystem inflammatory syndrome in children (MIS-C)
- Mitochondria assembly protein (Mas) 299
- MK-4482. *See* Molnupiravir
- Moderna vaccine 12
- Modifiable risk factors 152
- Molecular diagnostics, for COVID-19
- CRISPR-based technology 40
 - nucleic acid amplification testing 36
 - RT-LAMP 39–40
 - RT-qPCR 36–39
- Molnupiravir 172, 173, 301, 392–393
- Monoclonal antibodies (mAbs) 198–199, 271, 391, 472, 487
- MRI. *See* Magnetic resonance imaging (MRI)
- mRNA-based vaccines 10, 12, 505, 509, 510
- mRNA-1273 (Moderna) vaccine 113, 115, 476, 482
- Mucormycosis 326–327
- Multidisciplinary care 444
- Multisystem inflammatory syndrome in adults (MIS-A) 371–373
- Multisystem inflammatory syndrome in children (MIS-C) 52, 256–257, 371–373
- clinical manifestations 262–266
 - diagnosis 269–270
 - hyperinflammation in COVID-19 vs. 270
 - imaging findings 266
 - management 276–277
 - mucocutaneous findings 266
 - uveitis in 418–419
- Musculoskeletal complications 503
- Mycoplasma pneumoniae* 320, 322, 334
- Myelin oligodendrocyte glycoprotein (MOG) 348
- Myocardial infarction 526–527
- Myocardial injury
- acute coronary syndrome 364–365
 - acute myocarditis 368–369
 - biomarkers of 376
 - cardiogenic shock 368–369
 - direct viral 362, 364
 - non-STEMI 366–367
 - out-of-hospital cardiac arrest 367
 - pericarditis 369–371
 - pulmonary embolism 367–368
 - STEMI 365–366
 - thrombosis 367–368
- Myocarditis 201–202, 508–510
- n**
- Nafamostat 298
- Nafamostat mesylate (INN) 298
- Nanobodies. *See* Single-domain antibodies
- Nasal passages, adaptive immune response in 113
- NASA-Task Load Index 564
- National Academy of Medicine 570
- National Health Service 631
- National Institute for Health and Care Excellence 397, 548
- National Institutes of Health (NIH) 167, 184, 192, 240, 271, 273, 298
- Natriuretic peptides 202
- Neonatal testing 268–269
- Neonatal transmission 257
- Neuroinflammation 342–343
- Neurologic complications 497, 503–505. *See also*
- Central nervous system (CNS)
 - acute cerebrovascular events 351–352
 - acute myelitis 350–351
 - encephalopathy 346–350
 - Guillain-Barré syndromes 345–346
 - skeletal muscle injury 346
 - symptoms and complications 343–345
 - therapeutic strategies 352
 - viral transmission 342
- Neuromuscular blockade (NMB) 438–439
- Neuromuscular blockade agents (NMBAs) 188, 189

- Neuromuscular weakness 533
- Neuronal infection 341–342
- Neuro-ophthalmic complications 419–420
- Neuropsychiatric sequelae 546–547
 - cognitive impairment 547–548
 - delirium, management of 548
 - long COVID syndrome 548
 - pathophysiologic mechanisms of 547
- Neutralization assays 47–49
- Neutralizing antibody therapy 308
 - convalescent plasma therapy 308–309
 - recombinant monoclonal antibodies 308
- Next generation sequencing (NGS) technology 40–41
- N-hydroxycytidine (NHC)* 172
- Nicotinamide adenine dinucleotide phosphate
 - oxidase 2 (NOX-2) 343
- Nidovirales* 23
- NIH COVID-19 Treatment Guidelines
 - Panel 377–379
- NIPPV. *See* Noninvasive positive pressure ventilation (NIPPV)
- Nirmatrelvir (PF-07321332) 173–174
- Nitazoxanide 305–306
- Nitric oxide 138
- NIV. *See* Noninvasive ventilation (NIV)
- N95 masks 12–13, 235
- NMB. *See* Neuromuscular blockade (NMB)
- Non-frontline healthcare workers 565
- Noninvasive oxygen therapy 435, 438
- Noninvasive positive pressure ventilation (NIPPV) 183, 184, 186–187, 211
- Noninvasive ventilation (NIV) 235, 438, 457–459
- Nonmodifiable risk factors 152
- Nonnutritional energy 442–443
- Nonspecific interstitial pneumonia (NSIP) 85–87
- Nonsteroidal anti-inflammatory drugs (NSAIDs) 168, 274, 370
- North America, healthcare systems in 636–638
- North American Society for Cardiovascular Imaging 65
- Nosocomial bacterial pneumonia 243
- Novaferon 198
- NSIP. *See* Nonspecific interstitial pneumonia (NSIP)
- N-terminal pro-B-type natriuretic peptide (NT-proBNP) 152, 299
- Nucleic acid
 - coronavirus 25
 - SARS-CoV-2 26
 - vaccine 476–477
- Nucleic acid amplification testing (NAAT) 36, 42
- Nucleocapsid 25
- Nursing 454
 - advance care planning 461–462
 - building resilience 467
 - discharge planning 463–464
 - home care 464–465
 - humanization of care 465–466
 - inpatient management
 - adjusting nursing practices 455
 - limiting hospital visits 455
 - medications 459–461
 - nutritional management 461
 - oxygen delivery, modes of 457–459
 - personal protective equipment 454–455
 - pressure-related injuries 459
 - prone positioning intubated patients 457
 - prone positioning spontaneously breathing patients 456–457
 - reducing nonessential visits 456
 - staffing issues 455–456
 - interdisciplinary care team 462
 - moral and ethical distress 466
- Nutrition
 - in critically ill patient
 - ECMO 439
 - energy and protein requirements 440, 442
 - energy expenditure estimation 440, 442
 - GI intolerance 443–444
 - guidelines 431, 434–437
 - hyperglycemia 443
 - invasive mechanical ventilation 438
 - micronutrients and trace elements 443
 - neuromuscular blockade 438–439
 - noninvasive oxygen therapy 435, 438
 - nonnutritional energy 442–443
 - prone positioning 439
 - protein 443
 - screening and assessment 431, 432
 - follow-up, after hospital discharge 446–447
 - food service considerations 446
 - for hospitalized patients 428–429

Nutrition (*cont'd*)

- management 461
- in noncritically ill patient
 - interventions and monitoring 431, 433
 - screening and assessment 430–431
 - steroids 430
 - treatment 430
- nutrition-impacting symptoms 445
- post-ICU acute care management 444
- preplanning 446
- safety considerations 429–430
- supplements 168
- workforce and stock/supply considerations 444, 446

NVX-CoV2373 vaccine 480

O

Obstetric patients, COVID-19 symptoms in 134–136

Occupational risk assessment 593

Oceania/Pacific region, healthcare systems
in 628–629

Olfactory nerve 340–341

Olfactory training (OT) 127, 128

Oncologic surgery 398–399

Open reading frames (ORFs) 25, 26

Ophthalmology perspective

- anterior segment
 - corneal graft rejection 419
 - uveitis 418–419
- central retinal vein occlusion 421–422
- conjunctivitis 417–418
- CRAO 422
- episcleritis 418
- neuro-ophthalmic complications 419–420
- optic nerve 420–421
- orbital cellulitis 422–423
- orbital emphysema 424
- orbital inflammation 423
- retinal microangiopathy 421
- rhino-orbital mucormycosis 423–424

Optic nerve 420–421

Optic neuritis 420–421

Oral antivirals 169

- molnupiravir 172, 173

- nirmatrelvir (PF-07321332)/ritonavir 173–174

Oral corticosteroid therapy 130

Oral nutrition 439

Orbital cellulitis 422–423

Orbital emphysema 424

Orbital inflammation 423

Organizing pneumonia (OP) 84, 522

Oseltamivir 303

Otolaryngologic manifestation, of COVID-19 131

- facial nerve 131

- hearing loss 129–131

- sense of smell 126–128

- tinnitus 129–131

- voice disorders 127–129

Out-of-hospital cardiac arrest 367

Outpatient management 270

- anticoagulation 168–169

Anti-SARS-CoV-2 mAbs 169, 170

- bamlanivimab plus etesevimab 170–171

- bebtelovimab 171

- casirivimab plus imdevimab 171

- distribution of 171–172

- for mild-to-moderate outpatient 169–170

- side effects of 171

- sotrovimab 171

antivirals and anti-inflammatory treatments 169

dexamethasone 175

drugs not recommended for

- anti-IL-6 mAbs 175

- azithromycin 175

- chloroquine 175

- colchicine 176

- convalescent plasma 176

- hydroxychloroquine 175

- ivermectin 175

- Janus kinase inhibitors 175

- lopinavir/ritonavir 175–176

fluvoxamine 173–175

home monitoring 167

home supplemental oxygen 169

hydration and nutrition 167

inhaled budesonide 174

initial diagnosis 165

inpatient care vs. outpatient care 165–166

isolation 167

nutritional supplements 168

- ongoing pharmacologic management 168
- oral antivirals
 - molnupiravir 172, 173
 - nirmatrelvir (PF-07321332)/ritonavir 173–174
- potential conflicts of interest 165
- Oxford/AstraZeneca vaccine 503, 504
- thrombotic events 507–508

P

- Palliative care 403
- Papain-like protease (PLpro) 291, 303
- Papworth method 530
- Parasitic infection. *See* Strongyloidiasis
- Parenteral nutrition (PN) 431, 439, 440
- Parosmia 126–127
- Passive immunotherapy 487
- PCI. *See* Percutaneous coronary intervention (PCI)
- Pediatric inflammatory multisystem syndrome (PIMS) 371–373
- Pediatrics, COVID-19 in
 - clinical manifestations 258
 - atypical 261
 - cutaneous manifestations 260
 - disease severity 259
 - imaging findings 261–262
 - infection in infants 260
 - mild to moderate disease 259–260
 - MIS-C 262–266
 - neurologic symptoms 261
 - PASC 266
 - severe to critical disease 260
 - skin findings 261
 - diagnosis 266–267
 - ambulatory testing 268
 - in asymptomatic patients 267–268
 - coinfections 267
 - COVID-recovered patients 269
 - COVID toes 267
 - inpatient and perioperative testing 268
 - MIS-C 269–270
 - neonatal testing 268–269
 - in symptomatic patients 267
 - vaccinated persons 269
 - epidemiology 255–256
 - breastfeeding 258
 - of MIS-C 256–257
 - neonatal transmission 257
 - transmission in children 257
 - management
 - adjunctive therapy 275–276
 - antiviral therapy 273
 - convalescent plasma 275
 - fluid and electrolytes 272
 - hematology 272
 - inpatient 272
 - kinase inhibitors 276
 - MIS-C 276–277
 - monoclonal antibodies 271
 - outpatient 270
 - respiratory and cardiac 272
 - special populations 272–273
 - superimposed infections 276
 - supplemental agents 270–271
 - vaccines 278–279
- PEEP. *See* Positive end-expiratory pressure (PEEP)
- People of color (POC) 464
- Peptide-based vaccines 480
- Percutaneous coronary intervention (PCI) 365–367
- Perfusion abnormalities 77
- Pericarditis 369–371
- Perioperative testing 268
- Peripheral pulmonary vascular enlargement 76
- Personal protective equipment (PPE) 66, 67, 236, 365, 429, 454, 455, 465, 617
 - demand for 568–570
 - donning and doffing of 186, 209
 - respirators and masks 12–13
- Persons under investigation (PUIs) 66, 67
- PET-CT. *See* Positron emission tomography-CT (PET-CT)
- Pfizer-BioNTech vaccine 12, 278, 475, 481–482, 505, 506, 509
- PFT. *See* Pulmonary function test (PFT)
- Pharmacologic therapies
 - drug development 291, 293–296
 - for hospitalized patients 191–192
 - convalescent plasma 193
 - ivermectin 193–194
 - remdesivir 192
 - immune responses 292
 - virus life cycle 290–291

- PIMS. *See* Pediatric inflammatory multisystem syndrome (PIMS)
- Placebo-controlled trial 197
- PLACID trial 193
- Plaque reduction neutralization test (PRNT) 48
- PlasmAr trial 193
- Plasmodium falciparum* 158
- Platelet activation 362
- Pleural effusions 68, 83
- Pneumocystis jirovecii* pneumonia (PJP) 85, 327–328
- Pneumomediastinum 83
- Pneumothorax 69, 83
- Point-of-care (POC) testing 40
- Polo mint sign 74
- Positive end-expiratory pressure (PEEP) 187, 188, 238–239
- Positron emission tomography (PET) 89
- Positron emission tomography-CT (PET-CT) 518
- Postacute sequelae of SARS-CoV-2 (PASC) infection 266, 375–376
- Postanesthesia care units (PACUs) 210
- Post-COVID pulmonary fibrosis 525–526
- Post-COVID-19 vaccine imaging
 imaging misinterpretation 501
 local reactions 495–496
 lymphadenopathy 496, 498–501
 neurologic complications 497
 oncologic imaging with 502–503
 side effects
 injection-site reaction 503
 musculoskeletal complications 503
 myocarditis 508–510
 neurologic complications 503–505
 thrombotic complications 505–508
 systemic inflammation 496
 vaccine-induced adverse effects 495
 vaccine types 494–495, 497–498
- Post-hospital discharge care 167
- Post-ICU acute care management 444
- Post-ICU Presentation Screen tool 447
- Postimmunization encephalomyelitis 497
- Post-intensive care syndrome (PICS) 244–245
- Postmortem microscopy 138
- Posttraumatic stress disorder (PTSD) 245, 542–544, 555, 565, 567
- Postural orthostatic tachycardia syndrome (POTS) 374–375
- Postvaccination anaphylaxis
 management of 486
 symptoms of 485
- Postviral vagal neuropathy 129
- POTS. *See* Postural orthostatic tachycardia syndrome (POTS)
- Powered air-purifying respirator (PAPR) 365
- PPE. *See* Personal protective equipment (PPE)
- Pre-eclampsia-like syndrome 136
- PregCOV-19 Living Systematic Review 135
- Pregnancy, coronavirus and
 breastfeeding 137
 delivery 137
 maternal and neonatal outcomes 136
 physiologic and immunologic changes during 134
 symptoms 134–136
 vaccination 137
 vertical transmission and fetal complications 136
- Pressure-related injuries 459
- PRINCIPLE trial 174
- Prone therapy 188, 189
- Prone Positioning in Severe ARDS Patients (PROSEVA) study 188, 239
- Prophylactic Antiviral CRISPR in huMAN (PAC-MAN) cells 310
- Protective measures (PMs) 409, 414
- Protein-based vaccines 10, 480
- Protein E 26
- Protein M 24–26
- Protein N 26
- Protein S 24, 26–28
- Proteinuria 151
- Pseudomonas aeruginosa* 83, 322, 329
- Pseudoscience 582
- Psychological distress 539
 depression/anxiety 540–542
 posttraumatic stress disorder 542–544
 psychiatric disorders 539
 sleep dysfunction 544–546
- Psychological first aid model 570
- PTSD. *See* Posttraumatic stress disorder (PTSD)
- Pulmonary aspergillosis 324–325
- Pulmonary edema 86

Pulmonary embolism (PE) 69, 74–76, 367–368
 Pulmonary fibrosis, theoretical ways to prevent 532
 Pulmonary function test (PFT) 516, 525, 526
 Pulmonary inflammation models 300–301
 Pulmonary manifestations, of COVID-19 125–126
 Pulmonary parenchymal manifestations, on CT 70
 air bubble sign 73–74
 airways dilation 72
 atoll sign/reverse halo sign 73
 bronchial wall thickening 72–73
 consolidation 71
 crazy paving 71–72
 GGO 70–71
 halo sign 73
 interlobular septal thickening and intralobular lines 71
 Pulmonary vascular disease 532
 Pulse oximetry monitoring 167

q

Qualitative ELISA assays 47

r

Racial disparities 587–588, 599, 602
 Radiation therapy 396–397
 Radiographic Assessment of Lung Edema (RALE) 68
 Radiological Society of North America (RSNA) 90–92
 Radiologic diagnosis
 chest radiography 66–67
 chest x-ray 67–69
 cross-sectional imaging 67
 CT (*See* Computed tomography (CT))
 Fleischner Society 61–63
 guidelines, for reporting 90–92
 lung ultrasound 88–89
 MRI 89–90
 PET 89
 practical points 64–65
 technical considerations 65–66
 ultrasound machines 67
 World Health Organization 63
 Randomized controlled trial (RCT) 171, 193
 Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) 194, 195, 307

Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial 175, 239–240, 307, 352
 Rapamycin 115
 RCT. *See* Randomized controlled trial (RCT)
 RdRp. *See* RNA-dependent RNA polymerase (RdRp)
 Reactogenicity, of vaccine 473, 474
 Receptor-binding domain (RBD) 27, 28, 291
 Receptor-mediated virus entry 293
 Recombinant cytokine therapy 306
 Recombinant monoclonal antibodies 308
 Recombinant new coronavirus vaccine 480
 Recombinant SARS-CoV-2 vaccine 480
 Recovery phase 440
 RECOVERY trial. *See* Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial
 Recruitment maneuvers 189
 Reevaluation of Systemic Early Neuromuscular Blockade (ROSE trial) 188
 Refractory hypoxemia, of ventilated patients 188–191
 Remdesivir 115, 192, 273–274, 302–303, 378, 391
 Remdesivir triphosphate (RDV-TP) 302
 Renal replacement therapy (RRT) 203
 Renin-angiotensin-aldosterone system (RAAS) 299, 301
 Reproduction number (R0) 5–6
 Rescue therapies, for acute respiratory distress syndrome 189–191
 Resilience 467
 Resource allocation 581
 Respiratory droplets transmission 3
 Respiratory failure management 237–239
 Respiratory management 272
 Respiratory syncytial virus (RSV) 333–334
 Respiratory system, gross and histopathologic findings in 101–104
 Retinal microangiopathy 421
 Retinal vein occlusions (RVOs) 421–422
 Retrograde pathway, through neurons
 cranial nerves 341
 olfactory nerve 340–341
 Reverse transcription loop-mediated isothermal amplification (RT-LAMP) 39–40

Reverse transcription-polymerase chain reaction (RT-PCR) 64, 65, 67, 257, 323
 for COVID-19 and dengue 332, 333
 molecular-based 390

Reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR)
 applications and obstacles of 38–39
 principles of 36
 specimen collection for 36–38

Rhesus (Rh) antigen 153–154

Rhinocerebral mucormycosis 326, 327

Rhinolophus affinis 2

Rhino-orbital mucormycosis 423–424

Ribavirin (RBV) 303

Risk stratification
 ABO blood group
 blood type with higher susceptibility 154, 155
 COVID-19 clinical outcomes, of severity 154, 156
 genetics 154
 influenza viruses 154
 molecular mechanisms of 154, 158
 and Rh factor 153–154, 157
 SARS 154
 age 152, 153
 ethnicity 152, 153
 ML methods 158–159
 modifiable risk factors 152
 nonmodifiable risk factors 152
 potential biomarkers, for detection, severity, and mortality 149–152
 poverty and health inequality 153
 pregnant women 152
 SARS 154
 sex 153
 socioeconomic status 153, 154

Ritonavir 173–176, 197, 304

Rivaroxaban 168

RNA in situ hybridization studies 104

RNA-dependent RNA polymerase (RdRp) 25, 291, 303–304

RNAemia 37

ROX index 238

RT-qPCR. *See* Reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR)

Ruxolitinib 460

RVOs. *See* Retinal vein occlusions (RVOs)

S

Sarbecovirus 27

SARS. *See* Severe acute respiratory syndrome (SARS)

SARS-CoV-2. *See* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Secondary bacterial superinfections 204

Selective serotonin reuptake inhibitor (SSRI) 174

Self-directed prone position therapy 456

Self-proning, in COVID-19 185

Semiquantitative ELISA assays 47

Sense of smell 126–128

Sensorineural hearing loss (SNHL) 129, 131

Seroconversion 50

Sertoli cells 139

Serum amyloid A (SAA) 151

Serum C-reactive protein (CRP) 152

Serum D-dimer levels. *See* D-dimer levels

Serum 25-hydroxyvitamin D levels 168

SES. *See* Socioeconomic status (SES)

Severe acute respiratory syndrome (SARS) 22, 154, 515–517, 522, 615–616

Severe acute respiratory syndrome coronavirus (SARS-CoV) 1, 22, 34–35, 119

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1, 34, 65
 airborne droplets transmission 129
 antibody assay sensitivity and specificity 49–50
 antibody-based tests in 52–53
 antibody response
 and disease severity 50–51
 kinetics of 50, 51
 antigen detection 41, 42
 assay target selection 44–45
 binding assays 45–47
 in children 255–257
 chronic heart failure 379
 clinical manifestations of 258
 clinical spectrum of 259
 detection methods 35
 diagnostic methods for 165
 drug development for 291
 genome 25

- GI infection with 132, 134
- in heart transplant recipients 380
- hepatic injury by 133
- herd immunity to 12
- historical examples 2
- imaging findings of 261, 262
- immune detection of 292
- immunity, duration of 51–52
- infect all ages 7
- life cycle of 290, 293, 297
- lung infection 343
- molecular assays for 43
- morphology and nucleic acid 26
- neutralization assays 47–49
- origin of 27–28
- physical distancing 13
- physiologic changes and effect of 134
- pulmonary presentations and severity of 125
- serial interval for 5
- sexual transmission of 4–5
- sleep dysfunction and 544
- spike protein 26–27
- sports after 277–278
- surface contact transmission of 4
- testing 267
- therapeutics investigated for treatment of 294–296
- TMPRSS2 for 150
- variants 28–30
- ventilation effects on 14
- viral culture 42
- viral structure 45
- viral transmission 28
- Shoulder injury related to vaccine administration (SIRVA) 503
- Siamese neural networks (SNNs) 159
- Single-domain antibodies 311
- Single-nucleotide polymorphism 154
- Single-stranded RNA (ssRNA) 25
- Sinopharm (BBIBP) 10
- Sinopharm/Beijing Institute of Biological Products 484
- Sinopharm/Wuhan Institute of Biological Products co., Ltd. 484
- Sinovac Research and Development co., Ltd 484
- Skeletal muscle injury 346
- Skin, histopathologic findings in 109
- Sleep dysfunction 544
 - factors 544–545
 - in HCWs 555
 - management strategies and interventions 545–546
 - SARS-CoV-2 infection and 544
- Social distancing 575
 - mask wearing with 13
 - and self-quarantine 595
- Society of Advanced Body Imaging 65
- Society of Breast Imaging (SBI) 502
- Society of Cardiovascular Computed Tomography 65
- Society of Critical Care Medicine 184, 242
- Society of Thoracic Radiology (STR) 64–65
- Socioeconomic status (SES) 599
- SOLIDARITY trial 192, 273
- Sotrovimab 115, 171, 391
- South America, healthcare systems in 639–640
- South Asia, healthcare systems in 627–628
- Southeast Asia
 - healthcare systems in 628
 - healthcare workers impact in 561
- Southern Africa, healthcare systems in 622–623
- Spain, timeline implemented in 630, 631
- Specimen collection, for RT-qPCR 36
 - blood/plasma 37
 - breast milk 38
 - cerebrospinal fluid 37
 - feces 37–38
 - respiratory tract 36–37
 - saliva 37
 - urine 38
- Spermatogonia 139
- Spike (S) protein 26–27, 149, 291
- Sputnik V vaccine 479, 483–484
- Standard ICU care 242–244
- Standard of care (SOC) 191
- Staphylococcus aureus* 83, 276
- State Research Center of Virology and Biotechnology VECTOR, Russia 484–485
- Stenotrophomonas maltophilia* 329
- Steroids 309, 430
- Stranded Workers Action Network 594

Streptococcus pneumoniae 83, 276, 320
 Stress-induced hyperglycemia 443
 Stromectol. *See* Ivermectin
Strongyloides serology 330
 Strongyloidiasis 330
 ST-segment elevation myocardial infarctions (STEMIs) 364–366
 Surviving Sepsis COVID management guidelines 188
 Systemic hyperinflammatory response 364

t

Tamiflu. *See* Oseltamivir
 Targeted agents, cancer therapy 396
 Telehealth, diagnosis and follow-up 167
 Telemedicine 393
 Telmisartan 300
 Telogen effluvium 413
 Therapeutic classes
 antivirals 293, 297
 camostat 293, 297
 chloroquine 298–299
 hydroxychloroquine 298–299
 nafamostat 298
 upamostat 298
 Thromboembolic disease 200–201
 Thromboembolism 399
 Thrombosis 367–368
 Thrombotic complications
 Johnson & Johnson/Janssen vaccine-induced immune thrombotic thrombocytopenia 505–507
 Oxford/AstraZeneca thrombotic events 507–508
 Tinnitus 129–131
 TMPRSS2. *See* Transmembrane protease serine 2 (TMPRSS2)
 Tocilizumab 115, 119, 195–196, 240, 392, 460
 Tofacitinib 392
Torovirinae 24
Torovirinea 23
Torovirus 23–24
 Tracheal aspirate 37
 Tracheostomy 205–206
 Tracheostomy tube placement 241–242
 Transfer learning model 158, 159

Transmembrane protease serine 2 (TMPRSS2) 149–151, 158, 291, 293
 Traumatic stress 555
 Treatment disparities 600–601
Trichosporon asahii fungemia 328–329
 12-item General Health Questionnaire (GHQ-12) 561
 2019-novel coronavirus (2019-nCoV) 23
 Type I IFNs 306
 Tyrosine kinase inhibitors (TKIs) 396

u

UK Obstetric Surveillance System 136
 Ultrasound machines 67
 Umifenovir 303
 United Kingdom, healthcare workers impact in 558–559
 United Nations-Habitat 594–595
 United States
 disparities in exposure risk 586–587
 education 590–592
 neighborhood and environment 588–589
 prison and correctional system 589–590
 racial and ethnic disparities 587–588, 591
 tribal and rural communities 589
 unemployment and occupational risk 589
 healthcare workers impact in 557–558
 Universal Screening for SARS-CoV-2 Infection Among Pregnant Women at Elmhurst Hospital Center 135
 University of Oxford and AstraZeneca 483
 Unnamed vaccine 478, 484
 Upamostat 298
 Upper respiratory tract infections (URIs) 126, 127
 Urinary tract infection 138
 Urologic manifestations, of COVID-19
 infertility 139
 kidneys 137–138
 lower urinary tract infection 138
 organ function disorders 138–139
 Urticarial rash 411, 412
 US Centers for Disease Control and Prevention (CDC) 3, 7, 13, 65, 152, 165, 454, 455, 460, 569, 587, 590, 597
 guidelines 393, 395
 risk for exposure in schools 590

US criminal justice system 589
 US Department of Health and Human Services 581
 US Environmental Protection Agency 14
 US Food and Drug Administration (FDA) 481,
 482, 590
 US Veterans Health Administration system 234
 Utilitarianism 466
 Uveitis 418–419

V

Vaccination 472–473
 authorized candidate vaccines 474–475
 AZD1222/ChAdOx1/Covishield 483
 BBIBP-CorV 484
 BNT162b2/comirnaty 475, 481–482
 contraindication 474
 CoronaVac 484
 disparities in 603–607
 during pregnancy 137
 efficacy 473
 EpiVacCorona 484–485
 immunogenicity 473–474
 inactivated vaccines 478
 mRNA-1273 (Moderna) 482
 nucleic acid 476–477
 passive immunotherapy 487
 precaution 474
 prioritization and acceptance 486–487
 protein/peptide-based 480
 rates comparison between countries 632
 reactogenicity 473, 474
 Sputnik V 483–484
 storage and handling 473
 symptom management 485–486
 unnamed 484
 viral vector vaccines 479
 virus-like particle 481
 Vaccine Adverse Event Reporting System (VAERS)
 278, 505, 508
 Vaccine efficacy 53, 473
 Vaccine-induced immune thrombotic
 thrombocytopenia (VITT) 505, 508
 Vaccine-mediated herd immunity 12
 Vaccine-related lymphadenopathy.
 See Lymphadenopathy (LAP)
 VAERS. *See* Vaccine Adverse Event Reporting
 System (VAERS)
 Valsartan 299
 VAPs. *See* Ventilator-associated pneumonias (VAPs)
 Variants of concern (VoCs) 29
 Variants of high consequence (VoHCs) 29
 Variants of interest (VoIs) 29
 Vascular endothelial growth factor-D (VEGF-D) 151
 Vascular enlargement, peripheral pulmonary 76
 Vascular lesions 412–413
 Vasculitic lesions 413
 Vasculitis 102, 103
 Vasopressin 237
 Veklury. *See* Remdesivir
 Venous thromboembolism (VTE) 168, 169, 200, 201,
 244, 367, 368
 Venovenous extracorporeal membrane oxygenation
 (VV ECMO) 190
 Ventilation-perfusion single-photon emission computed
 tomography-CT (V/Q SPECT-CT) scan 527, 529
 Ventilator-associated pneumonias (VAPs) 243–244
 Ventilator management 238
 Vesicular pattern 411–412
 Viral culture 42–43
 Viral evasion 117
 Viral infection
 dengue 331–333
 influenza 331
 respiratory syncytial virus 333–334
 Viral neutralization assay 47–49
 Viral protein process inhibitors 303–304
 azithromycin 305
 disulfiram 304
 immunotherapy 306
 ivermectin 305
 lopinavir 304
 nitazoxanide 305–306
 ritonavir 304
 Viral replication inhibitors
 favipiravir 301
 molnupiravir 301
 oseltamivir 303
 remdesivir 302
 ribavirin 303
 umifenovir 303

Viral shedding 472
Viral vector vaccines 10, 479
Virions 24
Virologic dissemination, immune consequences of 116–117
Virus-like particle vaccine 481
Virus-specific pathophysiologic changes 526
Visitation, in ICU 236
VITT. *See* Vaccine-induced immune thrombotic thrombocytopenia (VITT)
Voice disorders 127–129
von Willebrand factor (VWF) activity 200
VTE. *See* Venous thromboembolism (VTE)

W

Weakened virus vaccines 10
Web-based global survey 414
West Africa, healthcare systems in 620–621
West African Health Organization 621
Whole-genome sequencing (WGS) 41
WHO Living Guidelines 167
World Health Organization (WHO) 1, 2, 6, 14, 23, 28, 39, 63, 184, 235, 240, 340, 559, 573

Z

Zoonotic spillover event 2–3

